# Brigatinib in Pediatric and Young Adult Patients With ALK+ ALCL, IMT or Other Solid Tumors

> **NCT04925609** · PHASE1,PHASE2 · RECRUITING · sponsor: **Princess Maxima Center for Pediatric Oncology** · enrollment: 65 (estimated)

## Conditions studied

- Anaplastic Large Cell Lymphoma, ALK-Positive
- Inflammatory Myofibroblastic Tumor
- Other Solid Tumor

## Interventions

- **DRUG:** Brigatinib

## Key facts

- **NCT ID:** NCT04925609
- **Lead sponsor:** Princess Maxima Center for Pediatric Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-08-18
- **Primary completion:** 2033-12
- **Final completion:** 2033-12
- **Target enrollment:** 65 (ESTIMATED)
- **Last updated:** 2025-12-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04925609

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04925609, "Brigatinib in Pediatric and Young Adult Patients With ALK+ ALCL, IMT or Other Solid Tumors". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT04925609. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*